Prolia 60mg Injection

Product Description

Prolia is the brand name for denosumab 60 mg injection, which is used primarily for the treatment of osteoporosis. Like Esentra, it is a monoclonal antibody that works by inhibiting RANKL, a protein that promotes the formation and function of osteoclasts (cells responsible for breaking down bone). By inhibiting RANKL, Prolia helps reduce bone loss and increases bone density, which lowers the risk of fractures, particularly in postmenopausal women and men with osteoporosis.

Prolia is typically administered once every six months as a subcutaneous injection. It is used to:

• Treat osteoporosis in postmenopausal women and men at risk of fractures.
• Increase bone mass in men receiving hormone ablation therapy for prostate cancer.
• Reduce the risk of bone fractures in certain other conditions, such as bone loss due to cancer treatment.

It's important to follow your healthcare provider's instructions regarding dosage and follow-up treatments, as Prolia affects bone turnover. Your doctor will also monitor for side effects and other considerations, like calcium levels, since denosumab can affect calcium metabolism.

If you're receiving or considering Prolia injections, make sure to discuss any concerns with your healthcare provider, particularly regarding the potential for side effects like infections, bone pain, or other reactions.